Industry Trends

Webinar Date/Time: Tue, Nov 19, 2024 11:00 AM EST

Webinar Date/Time: Wed, Oct 16, 2024 2:00 PM EDT

Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.

A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029.

A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.

Webinar Date/Time: Thursday, October 3, 2024 at 2pm EDT|11am PDT|7pm BST|8pm CEST

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Surviving a long road, novel next-generation treatment offers hope for major depressive disorder.

Key approval signals progress in addressing immune-mediated inflammatory diseases.

A breakthrough for biomarker-altered breast cancer—but broader challenges remain.

New cardiovascular indication builds on treatment’s fast-growing legacy.

Launch campaign ramped up for disease-modifying drug that targets rare and fatal form of hypertension.

The author discusses how to calm the nerves of workers during periods of uncertainty.

Abrams discusses how both new pharma and big pharma are reacting to each other and the current market.

Webinar Date/Time: Thu, Sep 12, 2024 11:00 AM EDT

Velys recently received 510(k) clearance from the FDA for planning and instrumenting spinal fusion procedures across the cervical, thoracolumbar, and sacroiliac spine.

An unexpected consequence of the COVID 19 pandemic has been a loss in trust of vaccines. Over the past three flu seasons, there has been a drop in vaccination rates that is alarming experts. Dr. Gregg Sylvester, chief health officer at CSL Seqirus, spoke with Pharmaceutical Executive about the causes of the decline and how important it is to get the rates back to normal.

Biocon Biologic’s chief commercial officer of advanced markets discusses the current market and potential trends for biosimilars.

The deals leader at EY Global Life Sciences discusses how the first half of 2024 fared compared to 2023’s strong ending.

Webinar Date/Time: Wed, Aug 28, 2024 11:00 AM EDT

Webinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT

Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.

JAMA study aims to discover how weight loss differs between patients receiving tirzepatide compared with semaglutide among a clinical population of overweight of obese adults.

A Harvard Business School Healthcare Alumni Association Q&A with Penn Center for Innovation’s Michael D. Moisel, MS, MBA.

A Q&A with Russell Reynolds’ Global Lead of CEO & Executive Transition Practice, Ty Wiggins, PhD.

Veeva’s vice president of global business consulting discusses recent trends in HCP access and how the pharma industry is reacting.

Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future growth and jockeying of biopharma’s top players.

A Q&A with Korn Ferry’s co-managing director of the Global Education Practice, Kenneth L. Kring.

Highlighted by notable company and product maneuvering at the top and the continued dramatic growth of therapeutic settings such as GLP-1s, Pharm Exec’s latest listing of the top global biopharma sales producers is proof-positive of an industry in transition.